GUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 financial results and provided a business update.
“We remain focused on our three strategic pillars of innovation, clinical evidence, and commercialization, all while actively managing our spending, resulting in meaningful progress in the transformation of the business,” said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. “The quarter was dominated by U.S. direct deals driving record average selling price and gross margin percentage for our business. We also received FDA clearance for our latest AI-powered software and drove strong progress on all our clinical programs, including our upcoming Alzheimer’s feasibility study.”
Third Quarter 2023 Financial Results
Nine Months Financial Results
2023 Financial Guidance
Conference Call
Hyperfine, Inc. will host a conference call at 1:30 p.m. PT/ 4:30 p.m. ET on Thursday, November 9, 2023, to discuss its third quarter 2023 financial results and provide a business update. Those interested in listening should register online by visiting https://investors.hyperfine.io/. and clicking on News & Events. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived audio webcast will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/.
About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom and CE certification in the European Union, and is also available in New Zealand.
The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about the Company’s financial and operating results, the Company’s goals and commercial plans, the Company’s Alzheimer’s feasibility study, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq Stock Market LLC; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s inability to successfully complete and generate positive data from the ACTION PMR study and the Alzheimer’s feasibility study; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
Marissa Bych
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
| September 30, 2023 | December 31, 2022 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 85,424 | $ | 117,472 | ||||
| Restricted cash | 548 | 771 | ||||||
| Accounts receivable, less allowance of $241 and $180 as of September 30, 2023 and December 31, 2022, respectively | 2,437 | 2,103 | ||||||
| Unbilled receivables | 682 | 454 | ||||||
| Inventory | 6,940 | 4,622 | ||||||
| Prepaid expenses and other current assets | 2,184 | 3,194 | ||||||
| Due from related parties | — | 48 | ||||||
| Total current assets | 98,215 | 128,664 | ||||||
| Property and equipment, net | 3,158 | 3,248 | ||||||
| Other long term assets | 1,691 | 2,139 | ||||||
| Total assets | $ | 103,064 | $ | 134,051 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 908 | $ | 678 | ||||
| Deferred grant funding | 548 | 771 | ||||||
| Deferred revenue | 1,454 | 1,378 | ||||||
| Due to related parties | 48 | — | ||||||
| Accrued expenses and other current liabilities | 5,253 | 5,976 | ||||||
| Total current liabilities | 8,211 | 8,803 | ||||||
| Long term deferred revenue | 1,086 | 1,526 | ||||||
| Total liabilities | 9,297 | 10,329 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Class A Common stock, $.0001 par value; 600,000,000 shares authorized; 56,537,946 and 55,622,488 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 5 | 5 | ||||||
| Class B Common stock, $.0001 par value; 27,000,000 shares authorized; 15,055,288 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 2 | 2 | ||||||
| Additional paid-in capital | 336,798 | 333,199 | ||||||
| Accumulated deficit | (243,038 | ) | (209,484 | ) | ||||
| Total stockholders' equity | 93,767 | 123,722 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 103,064 | $ | 134,051 | ||||
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Sales | ||||||||||||||||
| Device | $ | 1,728 | $ | 1,945 | $ | 6,670 | $ | 4,305 | ||||||||
| Service | 602 | 403 | 1,676 | 1,085 | ||||||||||||
| Total sales | 2,330 | 2,348 | 8,346 | 5,390 | ||||||||||||
| Cost of sales | ||||||||||||||||
| Device | 835 | 1,215 | 3,321 | 3,511 | ||||||||||||
| Service | 371 | 445 | 1,302 | 1,272 | ||||||||||||
| Total cost of sales | 1,206 | 1,660 | 4,623 | 4,783 | ||||||||||||
| Gross margin | 1,124 | 688 | 3,723 | 607 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 5,739 | 7,338 | 16,531 | 22,937 | ||||||||||||
| General and administrative | 4,615 | 3,198 | 16,103 | 26,570 | ||||||||||||
| Sales and marketing | 2,529 | 3,434 | 7,575 | 11,345 | ||||||||||||
| Total operating expenses | 12,883 | 13,970 | 40,209 | 60,852 | ||||||||||||
| Loss from operations | (11,759 | ) | (13,282 | ) | (36,486 | ) | (60,245 | ) | ||||||||
| Interest income | 1,021 | 170 | 2,920 | 203 | ||||||||||||
| Other income (expense), net | (19 | ) | (59 | ) | 12 | (63 | ) | |||||||||
| Loss before provision for income taxes | (10,757 | ) | (13,171 | ) | (33,554 | ) | (60,105 | ) | ||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||
| Net loss and comprehensive loss | $ | (10,757 | ) | $ | (13,171 | ) | $ | (33,554 | ) | $ | (60,105 | ) | ||||
| Net loss per common share attributable to common stockholders, basic and diluted | $ | (0.15 | ) | $ | (0.19 | ) | $ | (0.47 | ) | $ | (0.85 | ) | ||||
| Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted | 71,464,315 | 70,509,639 | 71,178,769 | 70,398,103 | ||||||||||||
HYPERFINE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (33,554 | ) | $ | (60,105 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 791 | 754 | ||||||
| Stock-based compensation expense | 3,453 | 8,859 | ||||||
| Loss on disposal of property and equipment, net | 48 | — | ||||||
| Payments received on net investment in lease | 25 | 6 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable, net | (334 | ) | (2,149 | ) | ||||
| Unbilled receivables | (228 | ) | (1,384 | ) | ||||
| Inventory | (2,494 | ) | 308 | |||||
| Prepaid expenses and other current assets | 1,010 | (439 | ) | |||||
| Due from related parties | 48 | 14 | ||||||
| Prepaid inventory | 281 | — | ||||||
| Other long term assets | 142 | 62 | ||||||
| Accounts payable | 229 | (1,522 | ) | |||||
| Deferred grant funding | (196 | ) | (1,403 | ) | ||||
| Deferred revenue | (364 | ) | 1,098 | |||||
| Due to related parties | 48 | (1,920 | ) | |||||
| Accrued expenses and other current liabilities | (776 | ) | 827 | |||||
| Net cash used in operating activities | (31,871 | ) | (56,994 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (546 | ) | (427 | ) | ||||
| Net cash used in investing activities | (546 | ) | (427 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | 146 | 2 | ||||||
| Net cash provided by financing activities | 146 | 2 | ||||||
| Net decrease in cash and cash equivalents and restricted cash | (32,271 | ) | (57,419 | ) | ||||
| Cash, cash equivalents and restricted cash, beginning of period | 118,243 | 191,160 | ||||||
| Cash, cash equivalents and restricted cash, end of period | 85,972 | 133,741 | ||||||
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | ||||||||
| Cash and cash equivalents | 85,424 | 132,482 | ||||||
| Restricted cash | 548 | 1,259 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 85,972 | $ | 133,741 | ||||
| Supplemental disclosure of noncash information: | ||||||||
| Noncash acquisition of fixed assets | $ | 54 | $ | — | ||||
| Write-off of notes receivable | $ | — | $ | 90 | ||||
| Last Trade: | US$0.90 |
| Daily Change: | -0.04 -4.56 |
| Daily Volume: | 185,895 |
| Market Cap: | US$51.930M |
December 03, 2024 November 21, 2024 November 19, 2024 November 12, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
